Amylyx Pharmaceuticals (AMLX) Competitors $6.30 -0.27 (-4.11%) Closing price 07/3/2025 01:00 PM EasternExtended Trading$6.24 -0.06 (-1.02%) As of 07/3/2025 04:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AMLX vs. TWST, ARWR, APLS, VCEL, RXRX, NAMS, DNLI, KNSA, APGE, and CGONShould you be buying Amylyx Pharmaceuticals stock or one of its competitors? The main competitors of Amylyx Pharmaceuticals include Twist Bioscience (TWST), Arrowhead Pharmaceuticals (ARWR), Apellis Pharmaceuticals (APLS), Vericel (VCEL), Recursion Pharmaceuticals (RXRX), NewAmsterdam Pharma (NAMS), Denali Therapeutics (DNLI), Kiniksa Pharmaceuticals International (KNSA), Apogee Therapeutics (APGE), and CG Oncology (CGON). These companies are all part of the "pharmaceutical products" industry. Amylyx Pharmaceuticals vs. Its Competitors Twist Bioscience Arrowhead Pharmaceuticals Apellis Pharmaceuticals Vericel Recursion Pharmaceuticals NewAmsterdam Pharma Denali Therapeutics Kiniksa Pharmaceuticals International Apogee Therapeutics CG Oncology Twist Bioscience (NASDAQ:TWST) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings. Do analysts prefer TWST or AMLX? Twist Bioscience presently has a consensus price target of $50.40, suggesting a potential upside of 32.25%. Amylyx Pharmaceuticals has a consensus price target of $11.00, suggesting a potential upside of 74.60%. Given Amylyx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Amylyx Pharmaceuticals is more favorable than Twist Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Twist Bioscience 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70Amylyx Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 2.92 Do insiders & institutionals hold more shares of TWST or AMLX? 95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. 3.0% of Twist Bioscience shares are held by insiders. Comparatively, 11.7% of Amylyx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is TWST or AMLX more profitable? Amylyx Pharmaceuticals has a net margin of 0.00% compared to Twist Bioscience's net margin of -54.98%. Twist Bioscience's return on equity of -33.48% beat Amylyx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Twist Bioscience-54.98% -33.48% -25.34% Amylyx Pharmaceuticals N/A -77.21%-63.84% Which has more risk & volatility, TWST or AMLX? Twist Bioscience has a beta of 2.41, meaning that its stock price is 141% more volatile than the S&P 500. Comparatively, Amylyx Pharmaceuticals has a beta of -0.49, meaning that its stock price is 149% less volatile than the S&P 500. Which has stronger earnings & valuation, TWST or AMLX? Twist Bioscience has higher revenue and earnings than Amylyx Pharmaceuticals. Twist Bioscience is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTwist Bioscience$312.97M7.30-$208.73M-$3.25-11.73Amylyx Pharmaceuticals$87.37M6.43-$301.74M-$3.11-2.03 Does the media prefer TWST or AMLX? In the previous week, Twist Bioscience had 1 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 3 mentions for Twist Bioscience and 2 mentions for Amylyx Pharmaceuticals. Twist Bioscience's average media sentiment score of 1.08 beat Amylyx Pharmaceuticals' score of 0.12 indicating that Twist Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Twist Bioscience 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amylyx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryTwist Bioscience and Amylyx Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks. Get Amylyx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMLX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AMLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMLX vs. The Competition Export to ExcelMetricAmylyx PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$561.59M$2.43B$5.54B$9.05BDividend YieldN/A1.78%5.24%4.02%P/E Ratio-2.038.9827.4320.22Price / Sales6.43682.84416.87118.64Price / CashN/A158.5936.8958.07Price / Book2.634.588.035.67Net Income-$301.74M$31.34M$3.18B$249.13M7 Day Performance-0.47%3.25%2.88%3.28%1 Month Performance24.75%7.08%3.69%5.56%1 Year Performance266.28%0.17%36.02%21.12% Amylyx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMLXAmylyx Pharmaceuticals3.5169 of 5 stars$6.30-4.1%$11.00+74.6%+255.9%$561.59M$87.37M-2.03200TWSTTwist Bioscience4.4798 of 5 stars$36.79+2.4%$50.40+37.0%-20.6%$2.20B$312.97M-11.32990Positive NewsARWRArrowhead Pharmaceuticals3.9951 of 5 stars$15.80-1.7%$43.71+176.7%-33.1%$2.18B$3.55M-11.29400Positive NewsAPLSApellis Pharmaceuticals4.4451 of 5 stars$17.31-0.7%$40.05+131.4%-49.2%$2.18B$781.37M-9.67770Trending NewsAnalyst ForecastAnalyst RevisionVCELVericel2.9146 of 5 stars$42.55+2.0%$61.14+43.7%-7.0%$2.14B$237.22M1,418.81300News CoveragePositive NewsRXRXRecursion Pharmaceuticals2.109 of 5 stars$5.06+0.6%$7.00+38.3%-28.4%$2.06B$58.84M-2.86400Analyst ForecastNAMSNewAmsterdam Pharma3.1099 of 5 stars$18.11-2.5%$42.89+136.8%-0.8%$2.03B$45.56M-9.634Positive NewsAnalyst UpgradeDNLIDenali Therapeutics4.6426 of 5 stars$13.99-0.8%$33.71+141.0%-31.0%$2.03BN/A-5.24430Positive NewsKNSAKiniksa Pharmaceuticals International3.3007 of 5 stars$27.67-1.3%$38.80+40.2%+45.8%$2.02B$423.24M-110.68220APGEApogee Therapeutics2.9043 of 5 stars$43.43+0.1%$94.60+117.8%+26.8%$2.00BN/A-12.0691News CoverageAnalyst ForecastInsider TradeHigh Trading VolumeCGONCG Oncology2.3866 of 5 stars$26.00+0.2%$58.67+125.6%-12.8%$1.98B$1.14M-17.2261 Related Companies and Tools Related Companies Twist Bioscience Competitors Arrowhead Pharmaceuticals Competitors Apellis Pharmaceuticals Competitors Vericel Competitors Recursion Pharmaceuticals Competitors NewAmsterdam Pharma Competitors Denali Therapeutics Competitors Kiniksa Pharmaceuticals International Competitors Apogee Therapeutics Competitors CG Oncology Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AMLX) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amylyx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amylyx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
